Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan

Sung Won Kim, Tetsuya E. Tanimoto, Noriyuki Hirabayashi, Seiichi Goto, Masahiro Kami, Satoshi Yoshioka, Toshiki Uchida, Kenji Kishi, Yuji Tanaka, Akio Kohno, Masaharu Kasai, Masakazu Higuchi, Masanobu Kasai, Shin Ichiro Mori, Takahiro Fukuda, Koji Izutsu, Hiroshi Sao, Takayuki Ishikawa, Tatsuo Ichinohe, Kengo TakeuchiKinuko Tajima, Ryuji Tanosaki, Mine Harada, Shuichi Taniguchi, Kensei Tobinai, Tomomitsu Hotta, Yoichi Takaue

Research output: Contribution to journalReview article

62 Citations (Scopus)

Abstract

We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.

Original languageEnglish
Pages (from-to)382-389
Number of pages8
JournalBlood
Volume108
Issue number1
DOIs
Publication statusPublished - 2006 Jul 1
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Kim, S. W., Tanimoto, T. E., Hirabayashi, N., Goto, S., Kami, M., Yoshioka, S., Uchida, T., Kishi, K., Tanaka, Y., Kohno, A., Kasai, M., Higuchi, M., Kasai, M., Mori, S. I., Fukuda, T., Izutsu, K., Sao, H., Ishikawa, T., Ichinohe, T., ... Takaue, Y. (2006). Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan. Blood, 108(1), 382-389. https://doi.org/10.1182/blood-2005-02-0596